本帖最后由 老马 于 2012-1-13 21:20 编辑 4 G0 o- U0 N1 S' e* Q/ D+ A
/ V: Z; e. k- w" Q$ e. Y% L/ g! q爱必妥和阿瓦斯丁的比较
% Y3 M9 o+ w: C+ o4 g4 E, f6 ~
9 K' ]$ c$ d9 M! u+ t" u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ F7 n+ H% @. e d( s$ b( ]
# a, {* y; I+ C& e2 |% d
$ n; z; }. ?" dhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
: e. n, q; w, K- `3 G. Q( `==================================================0 x1 u7 g. F) d6 U$ L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% i9 q$ m. f) v: P9 E# G" tPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# K6 G1 [; W9 M3 T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 w# g1 @: F* f5 X0 h* `% o
|